Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/9/2017
SIETES contiene 92006 citas

 
 
 1 a 20 de 590 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Young LA, Buse JB, Weaver MA, Vu MB, Mitchell M, Blakeney T, Grimm K, Rees J, Niblock F, Donahue KE, for the Monitor Trial Group. Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings. A randomized trial. JAMA Intern Med 2017;177:920-9. [Ref.ID 102017]
3. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
4. Cita con resumen
Driessen JHM, de Vries F, van Onzenoort H, Harvey NC, Neef C, van den Bergh JPW, Vestergaard P, Henry RMA. The use of incretins and fractures – A meta-analysis on population-based real life data. Br J Clin Pharmacol 2017;83:923-6. [Ref.ID 101971]
5. Cita con resumen
Anónimo. Beta blockers and the risk of CV events in type 2 diabetes. Diabetes in Control 2017:29 de julio. [Ref.ID 101936]
6.Enlace a cita original Cita con resumen
Anónimo. Actualización de insulinas. Infac: Información Farmacoterapéutica de la Comarca 2017;25:1-10. [Ref.ID 101631]
7.Enlace a cita original Cita con resumen
Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, Li S, Guyatt GH, Sun X. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 2017;357:j2499. [Ref.ID 101630]
8. Cita con resumen
Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017;376:2300-2. [Ref.ID 101628]
9. Cita con resumen
Anónimo. EMA’s CHMP recommends approval of biosimilar insulin lispro. DIA Daily 2017:2. [Ref.ID 101598]
10. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
11. Cita con resumen
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2017;40:468-75. [Ref.ID 101507]
12. Cita con resumen
Flory J. Will cardiovascular outcomes data on newer diabetes drugs bury the older agents?. JAMA Intern Med 2017;177:301-2. [Ref.ID 101462]
13. Cita con resumen
Anónimo. Lixisenatide for type 2 diabetes. Med Lett Drugs Ther 2017;59:19-21. [Ref.ID 101420]
14. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
15. Cita con resumen
Saiz Fernández LC. Ensayo EMPA-REG OUTCOME (empagliflozina) El poder de la verdad, la verdad del poder.. Boletín de Información Farmacoterapéutica de Navarra 2016;24:1-13. [Ref.ID 101347]
16. Cita con resumen
Anónimo. An update on the "gliptins". Drug Ther Bull 2016;54:138-41. [Ref.ID 101014]
17. Cita con resumen
Anónimo. Juno suspends clinical trial after two additional patient deaths. DIA Daily 2016:4. [Ref.ID 100980]
18. Cita con resumen
Anónimo. FDA approves diabetes drug. DIA Daily 2016:2. [Ref.ID 100975]
19. Cita con resumen
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2016:septiembre. [Ref.ID 100915]
20. Cita con resumen
Gargiulo G, Windecker S, da Costa BR, Feres F, Hong M-K, Gilard M, Kim H-S, Colombo A, Bhatt DL, Kim B-K, Morice M-C, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [Ref.ID 100878]
Seleccionar todas
 
 1 a 20 de 590 siguiente >>